SCHEMBL8220137

SCHEMBL8220137

Cc1c([S+]([O-])c2ccc(Cl)cn2)cc(C(N)=O)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.40
ELANE P08246 3/20 0.38
CCR1 P32246 2/20 0.38
PLA2G10 O15496 1/20 0.37
CYP1A2 P05177 2/20 0.37
MAT2A P31153 1/20 0.37
SYK P43405 1/20 0.36
MAPT P10636 3/20 0.36
RPS6KB1 P23443 1/20 0.36
AKT1 P31749 1/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
NPY5R Q15761 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136684 0.90 ELANE (0.47) NOTUMELANECCR1CYP1A2MAT2A
SCHEMBL8234359 0.85 NOTUM (0.46) NOTUMELANEPLA2G10CYP1A2SYK
SCHEMBL4131032 0.83 ELANE (0.46) NOTUMELANECCR1PLA2G10CYP1A2
SCHEMBL8218364 0.80 NOTUM (0.44) NOTUMELANEPLA2G10CYP1A2SYK
SCHEMBL8218340 0.80 NOTUM (0.44) NOTUMELANECCR1PLA2G10CYP1A2
SCHEMBL4131349 0.80 ELANE (0.47) NOTUMELANECCR1CYP1A2LMNA
SCHEMBL8063836 0.80 ELANE (0.47) NOTUMELANECYP3A4CYP2C9
SCHEMBL8234300 0.78 ELANE (0.40) NOTUMELANESYKNPSR1
SCHEMBL4136719 0.78 ELANE (0.58) NOTUMELANECYP2C9
SCHEMBL3967256 0.77 ELANE (0.49) NOTUMELANECYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003858-A1 MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS ASTRAZENECA AB (SE) 2011-01-06 US disclosed
WO-2008030158-A1 MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS ASTRAZENECA AB (SE) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003858-A1 MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS SERPINB1, ELANE, MPO NOTUM 1520/4885ELANE 2/4885CCR1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.